Division of Vascular Surgery, Department of Surgery, The Icahn School of Medicine at Mount Sinai, New York, NY, USA.
The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Vasc Endovascular Surg. 2024 Jul;58(5):548-553. doi: 10.1177/15385744231226047. Epub 2024 Jan 2.
Peripheral artery disease (PAD) can present as chronic limb threatening ischemia (CLTI) with ischemic pain and tissue loss. Progression of distal disease can lead to a "no option" or end-stage disease without traditional open or endovascular revascularization due to lack of pedal targets. Innovations in endovascular technology allow for the use of percutaneous deep vein arterialization (pDVA) to treat patients with CLTI. We describe our experience and technique for treating four patients with end-stage PAD with pDVA. Four patients with end-stage PAD were followed during and after pDVA creation. Technical success, complications, wound healing, and freedom from major amputation were analyzed. Patient data and outcomes were collected via chart review and at time of follow up appointments in vascular surgery clinic. Technical success was 100%, without post-procedural complications, and patients were continued on antiplatelet and anticoagulation. Three patients (75%) had successful wound healing, with 2 patients healing after transmetatarsal amputation (TMA), and 1 healing a distal foot ulceration that did not require surgery. One patient had worsening ischemic breakdown of a TMA, despite re-intervention on the pDVA, which required a below knee amputation (BKA). Freedom from major amputation was 75% overall, with an average follow-up time of 410 days post-procedure (Range: 113-563 days). Percutaneous deep vein arterialization attempts to provide blood flow to the preserved venous bed in patients with end-stage PAD. Exploration and utilization of this technique continues to expand in the modern vascular era. This case series highlights 4 patients with end-stage PVD who underwent pDVA, with 100% procedural success, and 75% limb salvage rate.
外周动脉疾病(PAD)可表现为慢性肢体缺血性威胁(CLTI),伴有缺血性疼痛和组织丧失。远端疾病的进展可导致“别无选择”或终末期疾病,由于缺乏足背靶点,传统的开放或血管内血运重建无法进行。腔内技术的创新允许使用经皮深静脉动脉化(pDVA)来治疗 CLTI 患者。我们描述了我们使用 pDVA 治疗 4 例终末期 PAD 患者的经验和技术。对 4 例终末期 PAD 患者进行 pDVA 治疗期间和之后的随访。分析了技术成功率、并发症、伤口愈合和免于大截肢的情况。通过病历回顾和血管外科诊所随访时收集患者数据和结果。技术成功率为 100%,无术后并发症,患者继续接受抗血小板和抗凝治疗。3 例(75%)患者伤口愈合成功,2 例经跖骨截肢(TMA)后愈合,1 例远端足部溃疡无需手术愈合。1 例患者尽管对 pDVA 进行了再干预,但 TMA 的缺血性破裂仍恶化,需要进行膝下截肢(BKA)。总体而言,免于大截肢的比例为 75%,平均术后随访时间为 410 天(范围:113-563 天)。经皮深静脉动脉化试图为终末期 PAD 患者保留的静脉床提供血流。在现代血管时代,这种技术的探索和应用不断扩大。本病例系列介绍了 4 例接受 pDVA 的终末期 PVD 患者,其手术成功率为 100%,保肢率为 75%。